Chi-Med's fruquintinib meets colorectal cancer PhII primary endpoint

Hutchison China MediTech has met the primary endpoint of progression-free survival in a Phase II clinical trial for its metastatic colorectal cancer candidate fruquintinib (HMPL-013), putting it one step closer to an approval in China, according to FiercePharmaAsia. The company's majority-owned unit, Hutchison MediPharma Ltd. R&D, said the secondary efficacy endpoints, including objective response rate, disease control rate and overall survival, are still being monitored. The trial compared fruquintinib against a placebo in patients with metastatic colorectal cancer. More from FiercePharmaAsia

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.